Clinical trials: Recurrence, active
Hepatocellular Carcinoma
Prevention of Postoperative Recurrence of Hepatocellular Carcinoma by Blocking RAK Cells With Anti-TIM-3
To compare the safety and efficacy of unmodified RAK cells and anti-TIM-3 blocked autologous RAK cells in preventing postoperative recurrence of HCC by postoperative TACE therapy combined with immune cell therapy.
- Trial name
- NCT05738980
- Testing
- Autologous RAK cells
- Where
- China
- Volunteers
- 88 people
- Sponsor
- Beijing Hospital
Idiopathic Recurrent Pericarditis
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068.
- Trial name
- NCT05673902
- Testing
- RPH-104
- Where
- Russia
- Volunteers
- 17 people
- Sponsor
- R-Pharm International, LLC
Glioblastoma, Gliosarcoma
Ultrasound-based Blood-brain Barrier Opening and Albumin-bound Paclitaxel and Carboplatin for Recurrent Glioblastoma
Paclitaxel is among the most active agents against glioblastoma in preclinical models. However, its clinical use has been hampered by the blood-brain barrier (BBB).
- Conditions
- Glioblastoma, Gliosarcoma, GBM, Glioblastoma Multiforme
- Trial name
- SC9/ABX (NCT04528680)
- Testing
- Sonication for opening of blood-brain barrier, Chemotherapy, albumin-bound paclitaxel, Chemotherapy, carboplatin
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Northwestern University
Ovarian Cancer
OCS Products Based on Exosome Technology Were Applied in the Recurrence Monitoring Study After the Initial Treatment of Baseline CA125-negative Ovarian Cancer
To study the performance of OCS products based on exosome detection technology in monitoring the recurrence of baseline CA125-negative ovarian cancer patients after initial treatment, and to explore reliable methods for…
- Trial name
- NCT07153705
- Volunteers
- 32 people
- Sponsor
- Beihua Kong
B-Cell Lymphoma Refractory, B-cell Lymphoma Recurrent
Axi-Cel as a 2nd Line Therapy in Patients With Relapsed/Refractory Aggressive B Lymphoma Ineligible to Autologous Stem Cell Transplantation
This is a phase 2, open-label, multicenter study evaluating axicabtagene ciloleucel (axi-cel) as a 2nd line therapy in patients with Relapsed/Refractory aggressive B-NHL who are ineligible to receive Autologous Stem Cell…
- Trial name
- NCT04531046
- Testing
- axicabtagene ciloleucel
- Where
- 16 sites in Belgium, France
- Volunteers
- 62 people
- Sponsor
- The Lymphoma Academic Research Organisation
Endoscopic Recurrence Rate, After Ileocolic Crohn 's Disease Surgery
Mesenteric Surgical Margin for Crohn's Disease Endoscopic Recurrence
Despite significant advancements in the treatment of Crohn's disease (CD), approximately 50% of patients undergo surgical intervention within ten years of diagnosis.
- Trial name
- NCT06241170
- Testing
- mesentery-guided resection margin, traditional resection margin
- Where
- China
- Volunteers
- 172 people
- Sponsor
- Sixth Affiliated Hospital, Sun Yat-sen University
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Prostate Cancer, Prostatectomy
High Dose Rate (HDR) Brachytherapy Salvage After Prostatectomy
The goal of this observational study is to learn about the long-term effects of HDR Brachytherapy in men with isolated local relapses after radical prostatectomy.
- Conditions
- Prostate Cancer, Prostatectomy, Local Recurrence of Malignant Tumor of Prostate, Radiotherapy; Complications
- Trial name
- NCT06982469
- Testing
- Brachytherapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Clinica Universidad de Navarra, Universidad de Navarra
Bipolar Disorder, Depressive Disorder
Prediction on the Recurrence of Manic and Depressive Episodes in Bipolar Disorder
Mood disorders (including bipolar disorder and major depressive disorder) are chronic mental disorders with high recurrent rate. The more the number of recurrence is, the worse long-term prognosis is.
- Trial name
- NCT05828056
- Testing
- Wearable activity tracker
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
CAR T Cell Therapy, CD33 Positive Acute Myelogenous Leukemia
Functionally Optimized CD33 CAR-T Cell Therapy Targeting Recurrent/Refractory Acute Myeloid Leukemia
Relapsed/refractory acute myeloid leukemia (R/R AML) currently lacks effective CAR-T therapeutic agents due to the absence of tumor-specific target antigens.
- Trial name
- NCT07538713
- Testing
- Functionally optimized CD33 CAR-T
- Volunteers
- 18 people
- Sponsor
- Qi deng
Refractory/Recurrent Central Nervous System Lymphoma
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
This study is designed to evaluate the safety and efficacy of cord blood-derived CAR-NK019 in the treatment of refractory/relapsed central nervous system lymphoma.
- Trial name
- NCT06827782
- Testing
- anti-CD19 CAR-NK cells
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma.
- Trial name
- NCT07613788
- Testing
- Rimegepant, Glofitamab, Obinutuzumab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Ruijin Hospital
Metastatic Olfactory Neuroblastoma
A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma
The goal of this clinical research study is to learn if zanzalintinib can help to control recurrent/metastatic ONB. The safety of zanzalintinib will also be studied.
- Trial name
- NCT07527169
- Testing
- Zanzalintinib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Postoperative Pain, Flare up
Impact of Integrating Two Nano Based Irrigants With Two Activation Techniques in Treatment of Teeth With Acute Pulpitis on Postoperative Pain and Flare up Incidence
This study aimed to evaluate and compare impact of integrating passive ultrasonic activation and laser activation with nano-chitosan and aloe vera in terms of postoperative pain and flare-up incidence in a randomized clinical…
- Conditions
- Postoperative Pain, Flare up, Flare Up, Symptom
- Trial name
- NCT07084194
- Testing
- Chitosan Nanoparticles Irrigant, aloe vera nanoparticles irrigant, Diode Laser Activation
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Minia University
Ischemic Stroke, Atrial Fibrillation
Cardiac Assessment for Recurrent Stroke Risk Evaluation in Atrial Fibrillation
Background Atrial fibrillation (AF) is the most common cardiac arrhythmia, affecting up to 10% of the elderly. Ischemic stroke is the main complication of AF and cardioembolism is one of the leading causes of ischemic stroke…
- Conditions
- Ischemic Stroke, Atrial Fibrillation, Cerebrovascular Disorders, Brain Diseases
- Trial name
- CARE-AF (NCT06954610)
- Testing
- No intervention
- Where
- Switzerland
- Volunteers
- 500 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Intracranial Vasospasm
Mechanical Intracranial Artery DilAtation Using Stent-retriever for Cerebral Vasospasm
Solitaire-x is a stent-retriever that is currently world-widely used, but is currently FDA-approved only as a revascularization device indicated for use to restore blood flow in the neurovasculature by removing thrombus for the…
- Trial name
- NCT06615882
- Testing
- stent-angioplasty & nimodipine infusion (During the stent (Solitaire-X) -angioplasty, IA nimodipine was also infused)
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Yonsei University
Breast Cancers
Partial Breast Re-irradiation for Breast Cancer
Breast cancer is the most common malignancy in women. Breast-conserving surgery (BCS) with adjuvant whole-breast irradiation (WBI) is currently the standard of care in the oncological treatment of primary breast cancer and offers…
- Trial name
- BREAST (NCT06954623)
- Testing
- Radiation Therapy
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Hospital Heidelberg
Recurrent Urinary Tract Infection
Gag Therapy for Recurrent Urinary Tract Infection Assessing Comparability to International Nitrofurantoin Gold Standard Study
The GT RACING is a study comparing the efficacy of HA-CS bladder installations with prophylactic antibiotics in the prevention of recurrent urinary tract infections (rUTI).
- Trial name
- GT RACING (NCT05652374)
- Testing
- Ialuril 50ml Prefill, Nitrofurantoin
- Where
- 3 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Locally Advanced or Metastatic Breast Cancer
A Study of Entinostat in Combination With Fulvestrant for the Treatment of Locally Advanced or Metastatic Breast Cancer
This study aims to evaluate the efficacy of Entinostat combined with Fulvestrant in HR+/HER2- advanced breast cancer patients with recurrence/progression after endocrine therapy (primary endpoint: progression-free survival…
- Trial name
- NCT07235618
- Testing
- Entinostat, Fulvestrant
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Sun Yat-sen University
Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma
Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients With Locally Recurrent Head and Neck Squamous Cell Carcinoma
This phase I trial studies the side effects and best dose of birinapant when given together with intensity modulated re-irradiation therapy (IMRRT) in treating patients with head and neck squamous cell carcinoma that has come…
- Conditions
- Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Sinonasal Squamous Cell Carcinoma
- Trial name
- NCT03803774
- Testing
- Biopsy Procedure, Birinapant, Computed Tomography
- Where
- 33 sites in United States
- Volunteers
- 13 people
- Sponsor
- National Cancer Institute (NCI)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.